Cryoport, Inc. (NASDAQ:CYRX) Holdings Boosted by D. E. Shaw & Co. Inc.

D. E. Shaw & Co. Inc. boosted its holdings in Cryoport, Inc. (NASDAQ:CYRX) by 20.1% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 408,385 shares of the company’s stock after acquiring an additional 68,474 shares during the period. D. E. Shaw & Co. Inc.’s holdings in Cryoport were worth $3,177,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. Avanza Fonder AB bought a new position in Cryoport in the fourth quarter worth about $64,000. Quarry LP bought a new position in Cryoport in the fourth quarter worth about $69,000. Nebula Research & Development LLC increased its stake in shares of Cryoport by 21.6% in the fourth quarter. Nebula Research & Development LLC now owns 12,442 shares of the company’s stock valued at $97,000 after purchasing an additional 2,207 shares during the period. Russell Investments Group Ltd. increased its stake in shares of Cryoport by 135.5% in the fourth quarter. Russell Investments Group Ltd. now owns 12,875 shares of the company’s stock valued at $100,000 after purchasing an additional 7,407 shares during the period. Finally, Olympiad Research LP acquired a new stake in shares of Cryoport in the fourth quarter valued at approximately $103,000. Institutional investors own 92.90% of the company’s stock.

Insider Activity at Cryoport

In other Cryoport news, CEO Jerrell Shelton sold 4,620 shares of the company’s stock in a transaction on Monday, March 17th. The stock was sold at an average price of $6.29, for a total value of $29,059.80. Following the transaction, the chief executive officer now owns 765,399 shares of the company’s stock, valued at approximately $4,814,359.71. This represents a 0.60% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders have sold 19,830 shares of company stock worth $118,353 over the last quarter. 10.00% of the stock is currently owned by company insiders.

Cryoport Price Performance

NASDAQ CYRX opened at $6.68 on Monday. Cryoport, Inc. has a 12 month low of $4.58 and a 12 month high of $12.58. The company has a debt-to-equity ratio of 0.48, a current ratio of 5.70 and a quick ratio of 5.32. The firm has a market capitalization of $334.92 million, a PE ratio of -1.98 and a beta of 1.92. The company’s 50 day simple moving average is $5.95 and its 200 day simple moving average is $6.86.

Cryoport (NASDAQ:CYRX) last posted its quarterly earnings data on Wednesday, May 7th. The company reported ($0.22) EPS for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.01. Cryoport had a negative net margin of 70.08% and a negative return on equity of 13.35%. The business had revenue of $41.04 million for the quarter, compared to analyst estimates of $56.19 million. As a group, equities research analysts forecast that Cryoport, Inc. will post -0.99 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts have commented on CYRX shares. Needham & Company LLC restated a “buy” rating and issued a $11.00 price target on shares of Cryoport in a research note on Thursday, May 8th. Morgan Stanley dropped their price target on shares of Cryoport from $8.00 to $7.00 and set an “equal weight” rating on the stock in a research note on Monday, May 5th. Guggenheim restated a “buy” rating and issued a $10.00 price target on shares of Cryoport in a research note on Wednesday, April 16th. Roth Mkm restated a “buy” rating and issued a $15.00 price target on shares of Cryoport in a research note on Tuesday, April 1st. Finally, UBS Group raised their price target on shares of Cryoport from $10.00 to $11.00 and gave the company a “buy” rating in a research note on Tuesday, April 1st. Two analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to data from MarketBeat, Cryoport presently has an average rating of “Moderate Buy” and a consensus price target of $11.00.

Cryoport Profile

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.